AbbVie Inc. sell NightTrain
Start price
31.08.21
/
50%
€102.32
Target price
31.08.22
-
Performance (%)
34.77%
End price
01.06.22
€137.90
Summary
This prediction ended on 01.06.22 with a price of €137.90. The price for AbbVie Inc. massively increased, which is bad news for the SELL prediction by NightTrain. Dividends of €3.64 are taken into consideration when calculating the performance. NightTrain has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| AbbVie Inc. | -0.909% | -0.909% | 6.410% |
| iShares Core DAX® | -1.670% | -1.001% | 10.864% |
| iShares Nasdaq 100 | -4.184% | -1.145% | 37.458% |
| iShares Nikkei 225® | -4.967% | -5.783% | 18.828% |
| iShares S&P 500 | -2.834% | -0.572% | 25.875% |
Comments by NightTrain for this prediction
In the thread AbbVie Inc. diskutieren
Sell AbbVie Inc.